Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™

Scorpius Holdings, Inc, an integrated contract development and manufacturing organization (“CDMO”), announced its collaboration with KaloCyte, a pioneering pre-clinical company in the field of therapeutic innovation. Under this initial project, Scorpius will utilize its scientific and technical expertise to enhance manufacturing efficiencies for KaloCyte’s lead candidate, ErythroMer™, a dried, bio-inspired artificial red blood cell designed to address life-threatening blood loss in situations where stored red blood cells are unavailable, unsuitable, or in short supply. The two companies are also evaluating opportunities to establish a commercial-scale manufacturing agreement.

“This collaboration reinforces Scorpius’ reputation as a trusted and innovative biomanufacturing partner,” said Jeff Wolf, CEO of Scorpius. “ErythroMer™ is a groundbreaking advancement that addresses critical healthcare challenges, and we are thrilled to contribute our scientific and technical expertise to this transformative initiative. By refining manufacturing processes for KaloCyte’s lead candidate, we are poised to accelerate its journey toward clinical success and expand its reach to patients who need it most. The prospect of commercial-scale manufacturing further emphasizes our shared commitment to making this life-saving therapy widely available.”

Elaine Haynes, President and CEO of KaloCyte, commented, “Scorpius BioManufacturing’s specialized focus, alignment with federal funding within the biodefense space and plans to grow their commercial production capabilities are a unique match for KaloCyte’s mission to develop a lifeline for when blood is not available as we prepare to advance to the clinic.”

This collaboration underscores Scorpius’ reputation as a trusted partner for biomanufacturing at all stages of development. With state-of-the-art facilities in San Antonio, TX, and a team of experienced professionals, Scorpius provides a comprehensive suite of services, including analytical testing, process development, and cGMP clinical manufacturing. The Company’s flexible and responsive approach enables it to support small businesses and innovative biotech companies in advancing their programs to the clinic and beyond.